TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02769325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium
Description: general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
Study: NCT01986660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Cream (SST-0225)
Study: NCT02140229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US power doppler
Description: Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACR/EULAR criteria
Description: Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
Study: NCT03270709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Study: NCT03985774

Intervention type: PROCEDURE
Intervention: Transcarotid revascularization
Description: The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
Study: NCT03272828

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobel Biocare titanium dental implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobel Biocare titanium dental implants
Study: NCT04465539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
Description: Hydroxyethyl starch dose is 500 cc in 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
Description: Hydroxyethyl starch dose is 500 cc in 6 hours
Study: NCT00895609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex, Neostigmine, Saline
Description: Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex, Neostigmine, Saline
Description: Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)
Study: NCT03594305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational seminar
Description: Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
Study: NCT04465539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone dose is 200-300 mg /day intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
Study: NCT02528656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Bell
Description: Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Compression System
Description: Patients will be submitted to a dynamic compression system.
Study: NCT01950845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop automated System (LIR®: learning intravenous resuscitator)
Description: Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: manual current practice by anesthesiologist team
Description: The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
Study: NCT03219489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic medical record alert
Description: An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records.
Study: NCT04060550

Intervention type: BIOLOGICAL
Intervention: Xolair
Description: This is in vitro mechanistic study. No drug will be given in vivo to patients.

Intervention type: BIOLOGICAL
Intervention: Xolair
Description: This is in vitro mechanistic study. No drug will be given in vivo to patients.

Intervention type: BIOLOGICAL
Intervention: Xolair
Description: This is in vitro mechanistic study. No drug will be given in vivo to patients.
Study: NCT04537507

Intervention type: PROCEDURE
Intervention: Coronary angiography
Study: NCT03447132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 500mg
Description: All patients in all arms will receive Fulvestrant 500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant 500mg
Description: All patients in all arms will receive Fulvestrant 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Dose reduction to 100 mg and 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Only for pre or peri menopausal patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Only for pre or peri menopausal patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT00612924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anaconda Stent Graft System
Description: Endovascular device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anaconda ONE-LOK Stent Graft System
Description: Endovascular device
Study: NCT03362398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin 25 mg
Description: Once weekly new anti-diabetic drug approved only in Japan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trelagliptin 100 mg
Description: Once weekly new anti-diabetic drug approved only in Japan
Study: NCT03970161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: routine ophthalmic examination
Description: Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
Study: NCT04185649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT8001 for injection
Description: 3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study: NCT05504304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation plus primary subtalar arthrodesis
Description: they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative management then calcaneoplasty and subtalar arthrodesis.
Description: they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
Study: NCT03926000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (PG)
Description: Pregabalin 150 mg one hour before the procedure as premedication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo (C)
Description: Placebo tablets one hour before the procedure as premedication.
Study: NCT05596617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bedtime melatonin
Description: Different doses of oral bedtime melatonin
Study: NCT02398851

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TacTic care model
Description: Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Patients receive care in a patient-centered, coordinated care model without the integration of technology
Study: NCT03999450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivational intervention (BMI)
Description: The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
Study: NCT02703389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Animated video explaining acute otitis media and antimicrobial stewardship.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: Contains same information as video.
Study: NCT04378205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.014-inch NiTi on one side /0.018-inch NiTi on the other side
Description: Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.016-inch NiTi on one side /0.018-inch NiTi on the other side
Description: Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
Study: NCT03740958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: 100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
Study: NCT02829281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Joint injection of Botulinum Toxin Type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: Joint injection of triamcinolone hexacetonide
Study: NCT01820403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portion size kcal of box lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portion size kcal of box lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portion size kcal of box lunch
Study: NCT02059889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Undergo FDG-PET
Study: NCT00943475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision
Description: circumcision by plastbell
Study: NCT04458922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT03534323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
Study: NCT03625349

Intervention type: DRUG
Intervention: NG-Monomethyl-L-Arginine
Description: Inhibitor of nitric oxide synthase.
Study: NCT04404114

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish AKI from normal kidney
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish AKI from normal kidney
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish AKI from CKD
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography to distinguish CKD from normal kidney
Description: Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
Study: NCT03344549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renal nutrition teleconsultation
Description: Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face consultation of renal nutrition
Description: Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
Study: NCT03340129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 3mg per kg every 3 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 3mg per kg every 3 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salvage therapy
Description: Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salvage therapy
Description: Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
Study: NCT00762138

Intervention type: DEVICE
Group type: OTHER
Intervention: AutoloGel System
Description: The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease
Study: NCT04050696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BQ 1.2
Description: BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
Study: NCT03819556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein in fresh milk
Description: Milk protein in increasing doses.
Study: NCT04518852

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib and PD-1 mAb
Description: the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)